Financial
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Oxipit
HQ Lithuania · Europe
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Not assessed
Customer rating
No reviews yet
Financial health
Band: Not assessedPrivately held
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Mar 2026: Swedish imaging company Sectra agreed to acquire Oxipit, developer of the autonomous chest X-ray AI ChestLink; the deal was expected to close in March 2026 and terms were not disclosed.
Cyber & information governance
No data breaches, cyber incidents or regulator actions involving Oxipit found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
No recalls, safety notices or regulator actions involving Oxipit or ChestLink found in HSH's search of the last 24 months.
Contract performance
No contract disputes, terminations or notable NHS/UK contracts involving Oxipit found in HSH's search of the last 24 months.
Competitors
No competitors linked yet.